Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit

Shumei Kato et al. J Natl Compr Canc Netw. 2017 Jul.

. 2017 Jul;15(7):863-866.

doi: 10.6004/jnccn.2017.0127.

No abstract available

Comment in

To the Editor: Predictive Markers and Precision Medicine.
Sorscher S. Sorscher S. J Natl Compr Canc Netw. 2017 Oct;15(10):1186. doi: 10.6004/jnccn.2017.7040. J Natl Compr Canc Netw. 2017. PMID: 28982743 No abstract available.

Transcriptomics and solid tumors: The next frontier in precision cancer medicine.
Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R. Tsimberidou AM, et al. Semin Cancer Biol. 2022 Sep;84:50-59. doi: 10.1016/j.semcancer.2020.09.007. Epub 2020 Sep 17. Semin Cancer Biol. 2022. PMID: 32950605 Free PMC article. Review.
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Okamura R, et al. JCO Precis Oncol. 2018;2018:PO.18.00183. doi: 10.1200/PO.18.00183. Epub 2018 Nov 15. JCO Precis Oncol. 2018. PMID: 30637364 Free PMC article.
Gut microbiota shapes cancer immunotherapy responses.
Lei W, Zhou K, Lei Y, Li Q, Zhu H. Lei W, et al. NPJ Biofilms Microbiomes. 2025 Jul 25;11(1):143. doi: 10.1038/s41522-025-00786-8. NPJ Biofilms Microbiomes. 2025. PMID: 40715107 Free PMC article. Review.
Precision Medicine: Disease Subtyping and Tailored Treatment.
Wang RC, Wang Z. Wang RC, et al. Cancers (Basel). 2023 Jul 28;15(15):3837. doi: 10.3390/cancers15153837. Cancers (Basel). 2023. PMID: 37568653 Free PMC article. Review.
Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies.
Gupta D, Kurzrock R, Lee S, Okamura R, Lim HJ, Kim KH, Sicklick JK, Kato S. Gupta D, et al. NPJ Precis Oncol. 2022 Mar 28;6(1):18. doi: 10.1038/s41698-022-00259-7. NPJ Precis Oncol. 2022. PMID: 35347205 Free PMC article.

1. Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015;16:1324–1334. - PubMed
1. Garay JP, Gray JW. Omics and therapy - a basis for precision medicine. Mol Oncol 2012;6:128–139. - PMC - PubMed
1. Schwaederle M, Zhao M, Lee JJ, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol 2016;2:1452–1459. - PubMed
1. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726–736. - PMC - PubMed
1. Wheler JJ, Janku F, Naing A, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res 2016;76:3690–3701. - PubMed